37th Annual J.P. Morgan Healthcare Conference January 9, 2019

台灣浩鼎生技股份有限公司 腫瘤免疫與標靶抗癌療法全球創新者 黃秀美總經理 37th Annual J.P. Morgan Healthcare Conference January 9, 2019

This presentation contains certain forward-looking statements. Safe Harbor Statement These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future, or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1. Pricing and product initiatives of competitors 2. Legislative and regulatory developments and economic conditions 3. Delay or inability in obtaining regulatory approvals or bringing products to market 4. Fluctuations in currency exchange rates and general financial market conditions 5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products 6. Increased government pricing pressures 7. Interruptions in production 8. Loss of or inability to obtain adequate protection for intellectual property rights 9. Litigation 10. Loss of key executives or other employees 11. Adverse publicity and news coverage OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc. 2

Agenda 1 2 3 4 Company Introduction Globo Series Science Leadership Novel Cancer Pipeline Key Milestones and Inflection Points 3

Agenda 1 2 3 4 Company Introduction Globo Series Science Leadership Novel Cancer Pipeline Key Milestones and Inflection Points 4

台灣浩鼎生技股份有限公司 (TPEx: 4174.TWO) www.obipharma.com 設立日期 : April 29, 2002 Shanghai CHINA 上櫃日期 : March 23, 2015 市值 (Jan. 4, 2019): 上櫃募資金額 : 帳上淨現金 : ~US$920M (~NT$28.5B) ~US$200M (~NT$6.2B) ~US$115M Hong Kong CHINA Global HQ Taipei TAIWAN San Diego USA 員工人數 : 117 Melbourne AUSTRALIA 5

具豐富國際經驗的管理團隊 張念慈博士創辦人暨董事長 黃秀美總經理 游丞德博士 Chief Science Officer and Executive VP Kevin Poulos Chief Commercial Officer 詹孟恭 Chief Financial Officer 林曉瑩 General Counsel Mitch Che Chief Operating Officer OBI USA 蔡承恩醫師, 博士 VP Medical and Clinical Development David Hallinan, PhD VP Regulatory Affairs 賴建勳博士 VP Research 李淑華博士 VP Statistics and Biometrics 6

科學與醫學顧問群 翁啟惠, PhD 閻雲, MD, PhD Stephan Landisch, MD 楊泮池, MD, PhD 陳鈴津, MD, PhD Russell Greig, PhD 陳紹琛,MD, PhD Tillman Pearce, MD 石全, PhD 汪裕, MD 7

OBI Pharma Is at the Forefront of Innovation in Cancer Therapy INNOVATION DRIVERS Explosion in Immunotherapy Driven by PD1/PD-L1 and Novel Antigens/MOAs Continued Growth of Targeted Therapy Driven by CAR T Improved Chemotherapies Tumor-Specific Improved Formulations INNOVATION TRENDS Synergistic Combinations Anchored by PD-1/PD-L1 Antibody-Drug Conjugates (ADCs) Bispecific Antibodies Targeted Prodrugs IV Oral Therapy OBI INNOVATION OBI Pharma is Focused on: Novel Antibodies Innovative Technologies Synergistic Combinations Tumor-Specific Chemotherapy CAR T, chimeric antigen receptor T-cell therapy; IV, intravenous; MOA, mechanism of action; PD-1, programmed death 1; PD-L1, programmed death ligand 1. 8

OBI Has Transformed Into a Multi-Asset Company With a Diversified Portfolio of Novel Therapies GSL mab Antibody-Drug Conjugate Bispecific mab Targets: Assays: Globo H (+), SSEA-4 (+), AKR1C3 (+) Tumors Globo H, AKR1C3 GSL Vaccine Targeted Prodrug mab, monoclonal antibodies; GSL, glycosphingolipid. 9

Agenda 1 2 3 4 Company Introduction Globo Series Science Leadership Novel Cancer Pipeline Key Milestones and Inflection Points 10

OBI Pharma is the only company with a mid-to-late-stage Immuno-Oncology pipeline targeting the Globo Series of Glycosphingolipids: Globo H, SSEA-3, SSEA-4 11

Globo Series: A Unique Class of Glycosphingolipids (GSLs) Involved in Tumor Development and Survival GSLs Globo Series GSLs β3 α2 α3 SSEA-3 Globo H SSEA-4 Ceramide Ceramide Ceramide Glc GalNAc Gal Sialic Acid Fuc Functional Roles of Lipids and Membranes William Dowhan, Mikhail Bogdanov, Eugenia Mileykovskaya Department of Biochemistry and Molecular Biology, The University of Texas at Houston Medical School, Houston, Texas. 12

Globo Series 抗原表現於多種上皮細胞癌 Cancers Globo H* SSEA-3 SSEA-4* Esophagus 食道癌 100% 0% 50% Stomach 胃癌 100% 50% 67% Pancreas 胰臟癌 75% 38% 100% Prostate 攝護腺癌 25% 25% 100% Liver 肝癌 90% 40% 60% Ovary 卵巢癌 56% 22% 89% Colon 大腸癌 86% 0% 71% Kidney 腎癌 86% 0% 83% Mouth 口腔癌 85% 15% 62% Cervix 子宮頸癌 25% 50% 75% Breast 乳癌 61% 26% 74% Brain 腦癌 35% 53% 71% Lung 肺癌 65% 25% 65% Bile duct 膽管癌 60% 20% 40% * >50% expression highlighted. Note: Expression of Globo Series was determined by flow cytometry; More than 15% is regarded as positive. Lou YW, et al. Proc Natl Acad Sci U S A. 2014;111(7):2482-2487. 13

Globo H 於腫瘤存活扮演必要角色 促進免疫抑制 促進腫瘤存活訊號傳導 Lymphocytes Ub Ub Degradation Notch1 促進血管新生 Endothelial Cells TRAX Ca 2+ Tumor Shedding of Globo H Ceramide Kinase Kinase Kinase Tumor Cells Tumor Survival Cancer Res. 2016. AACR Special Conference Abstract A20. Cheng JY, et al. Cancer Res. 2014;74(23):6856-6686. J Cancer Sci Ther. 2013;5(7):264-270. OBI Data on File. 14

Agenda 1 2 3 4 Company Introduction Globo Series Science Leadership Novel Cancer Pipeline Key Milestones and Inflection Points 15

浩鼎的多元化抗癌新藥研發產品線 抗癌新藥 類型 作用靶點潛在適應症新藥探索臨床前研究臨床一期臨床二期臨床三期 Adagloxad Simolenin 疫苗 Globo H 三陰性乳癌卵巢癌 OBI-833 疫苗 Globo H 數種癌症 OBI-888 單株抗體 Globo H 數種癌症 OBI-999 OBI-898 抗體小分子藥物複合體單株抗體 Globo H SSEA-4 數種癌症數種癌症 OBI-866 疫苗 SSEA-4 乳癌 OBI-3424 小分子化療前驅藥 AKR1C3 肝癌攝護腺癌白血病 ALL, acute lymphoblastic leukemia; CRPC, castration-resistant prostate cancer; HCC, hepatocellular carcinoma; TNBC, triple-negative breast cancer. 16

Adagloxad Simolenin First-in-Class Active Immunotherapy Inducing Globo H Antibodies 17

Adagloxad Simolenin 引發 ADCC 以及 CDC 促使腫瘤細胞凋亡 Globo H KLH IgG Adagloxad Simolenin MHC TCR T Cell IgM Complement Antigen-Presenting Cell B CTL Anti-Globo H IgG Anti-Globo H IgM ADCC Antibody-Dependent Cellular Cytotoxicity Tumor cell CDC Complement-Dependent Cytotoxicity APC, antigen-presenting cell; CTL, cytotoxic T-lymphocyte; KLH, keyhole limpet hemocyanin; MHC, major histocompatibility complex; TCR, T-cell receptor.. 18

從 Adagloxad Simolenin 臨床二期試驗 ( 以轉移性乳癌患者為受試對象 ) 學到 腫瘤的 Globo H 表現量與無惡化存活期相關 疫苗引發抗 Globo H 的 IgG 抗體濃度與無惡化存活期 (PFS) 有正相關 接受完整 9 次注射的受試者有較佳的無惡化存活期 PFS, progression-free survival. Clinicaltrials.gov. Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects. NCT01516307 19

Adagloxad Simolenin 全球臨床三期試驗 ( 以早期高復發風險之三陰性乳癌病患為受試者 ) 早期高復發風險之三陰性乳癌共 668 位受試者 Neoadjuvant patients with residual disease, or Adjuvant patients with 4 axillary nodes Globo H positive ECOG PS 0-1 R 1:1 實驗組 Adagloxad Simolenin (Adagloxad Simolenin 30 μg + OBI-821 100 μg) 334 位受試者 用藥期間約兩年 ( 共 21 針 ) 對照組安慰劑 (phosphate-buffered saline) 334 位受試者 主要試驗指標 : 次要試驗指標 : 期中分析 : 預估試驗期間 : 主管機關核准進行 : 無 侵襲性疾病 存活期 (Invasive Disease-Free Survival, IDFS) 整體存活期 生活品質 安全性 耐受性 侵襲性疾病 發生的個案數達預估數的 70% 時進行評估兩年招募受試者 三年無侵襲性疾病存活期評估, 加上兩年整體存活期評估美國 澳洲 台灣 香港 ECOG PS, Eastern Cooperative Oncology Group Performance Status. Clinicaltrials.gov. Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. NCT03562637 20

OBI-888 作用於 Globo H 之首創單株抗體 21

OBI-888 在五種動物模型中顯示出抑制腫瘤效果 癌症種類動物模型劑量 (mg/kg) 給藥方式 在最高劑量之腫瘤生長抑制 (TGI), % 乳癌 MCF7 1, 3, 10 Q2W x 6 85 乳癌 HCC-1428 3, 10, 30 Q2W x 6 55 胰臟癌 HPAC 5, 20, 80 Q2W x 5 47 直腸癌 SW480 100 Q2W x 4 49 肺癌 NCI-H526 10, 30, 100 Q2W x 5 43 Q2W, every 2 weeks; TGI, tumor growth inhibition. OBI Data on File. 22

OBI-888 具高度腫瘤特異性 (Highly Tumor Specific) NORMAL MICE MCF7-TUMOR BEARING MICE Distribution of labeled Globo H mab (OBI-888) in the tumor of the MCF7 mouse Eppendorf tubes for reference purposes OBI Data on File. 23

OBI-888 保護 T 細胞免於 Globo H 抑制 Intensity of T-cell's "Glo" (RLU) 40000 30000 20000 10000 0 Globo H Ceramide OBI 888 aapc/cho K1 aapc/cho-k1 Cells T-cell activity with Globo H Ceramide OBI-888 aapc, artificial antigen-presenting cells; CHO-K1, Chinese hamster ovary K1 cells. PD-1 effector cells were pretreated with 40 µm Globo H Ceramide for 20 hours in the presence or not of 10 µm OBI-888, and then incubated with aapc/cho-k1 cells for 6 hours. The RLU signal was determined after 10 minutes developing with Bio-Glo Luciferase Assay Reagent. Each treatment was performed in quintuplicate. RLU shown as mean ± standard deviation (SD). OBI Data on File. + + + 4-fold increase 24

OBI-888 與 Anti-PD-L1 單株抗體併用顯示出保護 T 細胞活性之加乘效果 aapc/cho K1 Cells PD-L1 aapc/cho-k1 Cell T-cell activity in PD-L1(+) cells with Globo H Ceramide OBI-888 and a-pd-l1 mab 8-fold increase a-pd-l1 mab 2-fold increase OBI Data on File. Globo H Ceramide a-pd-l1 mab OBI-888 - + - + + - - + + + - - - - + 25

OBI-888 具備發展合併療法的潛力 在第一期非小細胞肺癌 (Stage 1 NSCLC),Globo H 的表現不但與 PD-L1 的表現相關 (P=0.021), 亦與 EGFR (ADC, P=0.026) 以及 PI3K 的表現相關 (SqCC, P<0.001) Globo H overexpressed in 38.6% of patients with Stage I NSCLC 21% Dual Expression PD-L1 overexpressed in 46% of patients with Stage 1 NSCLC N = 228 patients with Stage 1 NSCLC, including both ADC and SqCC ADC, adenocarcinoma; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; SqCC, squamous cell carcinoma. Yang CY, et al. Cancer Biomark. 2017;21(1):211-220. 26

正在進行中之 OBI-888 臨床試驗 多種固體腫瘤胰臟癌 乳癌 胃癌 食道癌 大腸直腸癌 肺癌 Part 1 劑量遞增階段 (DOSE ESCALATION) OBI-888 Part 2 族群擴增階段 (COHORT EXPANSION) OBI-888 以 IDE-Approved Assay 量測 Globo H 表現量 Apostolia M Tsimberidou, MD, PhD Department of Investigational Cancer Therapeutics Division of Cancer Medicine IDE, Investigational Device Exemption. Clinicaltrials.gov. Study to Evaluate the Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. NCT03573544. 27

OBI-999 作用於 Globo H 之抗體小分子藥物複合體 (Antibody-Drug Conjugate, ADC) 28

OBI-999 以腫瘤特異之 Globo H 抗原為作用標的 對癌細胞具特異性之細胞毒素於 Globo H 高表現之癌細胞釋放 特殊之連接技術 (linker technology) 能維持抗體的安定性以及一致的 drug-to-antibody ratio (DAR) 全球獨家授權使用 ThioBridge 技術於 Globo Series 抗體小分子藥物複合體 (ADC) ADC Utilizing Novel Site-Specific Linker Technology ThioBridge ThioBridge is the registered trademark of Abzena 29

OBI-999 在四種動物模型中顯示腫瘤抑制效果 癌症種類 動物模型 劑量 (mg/kg) 給藥方式 在最高劑量之腫瘤反應或腫瘤生長抑制 (TGI), % 乳癌 MCF7 1, 3 QW x 6 or Q3W x 2 完全反應 胃癌 NCI-N87 1, 3,10 QW x 4 完全反應 (CR achieved at both 3 and 10 mg/kg) 完全反應 = 腫瘤消失 (Tumor Free) 胰臟癌 HPAC 10 QW x 4 完全反應 肺癌 PDX LU-01-0266 1, 3, 10 QW x 4 完全反應 PDX, patient-derived xenograft; TGI, tumor growth inhibition; QW, every week; Q3W, every 3 weeks. OBI Data on File. 30

OBI-898 以腫瘤 SSEA-4 抗原為作用標的之單株抗體

SSEA-4 抗原高度特異表現於多種癌細胞 (Highly Specific to Cancer Cells) Cancers Globo H* SSEA-3 SSEA-4* 食道癌 Esophagus 100% 0% 50% 胃癌 Stomach 100% 50% 67% 胰臟癌 Pancreas 75% 38% 100% 攝護腺癌 Prostate 25% 25% 100% 肝癌 Liver 90% 40% 60% 卵巢癌 Ovary 56% 22% 89% 大腸直腸癌 Colon 86% 0% 71% 腎癌 Kidney 86% 0% 83% 口腔癌 Mouth 85% 15% 62% 子宮頸癌 Cervix 25% 50% 75% 乳癌 Breast 61% 26% 74% 腦癌 Brain 35% 53% 71% 肺癌 Lung 65% 25% 65% 膽管癌 Bile duct 60% 20% 40% Note. Expression of Globo Series Antigens was determined by flow cytometry; >15% expression was regarded as positive. Lou YW, et al. Proc Natl Acad Sci U S A. 2014;111(7):2482-2487. 32

OBI-898 阻隔 SSEA-4 與免疫檢查點 Siglec-9 的結合 ITIM, immunoreceptor tyrosine-based inhibitory motif; P, phosphate; Siglec-9, sialic acid-binding Ig-like lectin 9 OBI Data on File. 33

SSEA-4 會提高多重抗藥性蛋白質 (MDR1) 的表現量 SSEA-4 upregulates multidrug resistance protein 1 (MDR1) expression through csrc and β-catenin signaling MDR1 overexpression is most commonly detected in drugresistant cancers MDR1 encodes for P-glycoprotein that extrudes anticancer drugs Liu YY, et al. Molecular Cancer. 2010;9:145. High expression of SSEA-4 was found in residual tumor cells surviving chemotherapy and in samples from patients with metastatic cancer who relapsed after neoadjuvant chemotherapy Aloia A, et al. Breast Cancer Research. 2015;17:146. GCS, glucosylceramide synthase; GEM, glycosphingolipids-enriched microdomains; GlcCer, glucosylceramide; Tcf4, T-cell factor 4; FAK, focal adhesion kinase; csrc, proto-oncogene (Schmidt-Ruppin A-2); Gb3, globotriaosylceramide; Gb5, globopentaosylceramide; MSGb5, monosyl-gb5. 34

OBI-898 可降低 EGFR 蛋白的表現量如同 Tyrosine Kinase Inhibitor (TKI) Osimertinib (Targrisso ) 3 mpk 30 mpk OBI-898 1 mpk 5 mpk Osimertinib ** EGFR L858R Western Blot was highly correlated to hematoxylin and eosin stain; P<0.01. Targrisso is the registered trademark of AstraZeneca. OBI Data on File 35

因應 TKI 治療後迅速出現之抗藥性 ( 對於 EGFR 突變癌症新療法之需求不墜 ) Major TKI Products and Companies PRODUCT GENERIC NAME COMPANY FIRST APPROVAL First Generation Second Generation Third Generation Iressa Gefitinib AstraZeneca 2003 Tarceva Erlotinib Genetech (Roche)/ Astellas 2004 Gilotrif Afatinib Boehringer Ingelheim 2013 Vizimpro Dacomitinib Pfizer Sept 2018 Tagrisso Osimertinib AstraZeneca 2015 Table summarized by OBI. 36

OBI-3424 以表現 AKR1C3 的腫瘤為標的之小分子化療前驅藥 37

具腫瘤特定性 (Tumor-Specific) 之小分子化療前驅藥 (Prodrug)OBI-3424 OBI-3424 經腫瘤內 AKR1C3 酵素活化後, 會釋放出細胞毒殺劑 Tumor Cell OBI-3424 AKR1C3 Enzyme Present Prodrug AKR1C3 Active drug Tumor Cells Killed Healthy Cell No AKR1C3 Minimal Impact on Healthy Cells NADPH, nicotinamide adenine dinucleotide phosphate. 38

以存在未被滿足醫療需求, 以及 AKR1C3 酵素高表現之癌症為目標, 開發 OBI-3424 潛在適應症 CANCER CLINICAL DEVELOPMENT STATUS AKR1C3 EXPRESSION,* % 肝癌 Liver Ongoing 89 對去勢療法產生抗性之攝護腺癌 CRPC T 細胞急性淋巴性白血病 T-ALL Ongoing 58 P1 IND planned in Q2/2019 (NCI funded PPTC) 86 腎癌 Kidney n/a 64 膀胱癌 Bladder n/a 66 胃癌 Stomach n/a 59 ** AKR1C3 Expression: Guise CP, et al. Cancer Res. 2010;70(4):1573-1584. CRPC, castration-resistant prostate cancer; IND, Investigational New Drug Application; n/a, not applicable; NCI, National Cancer Institute; PPTC, Pediatric Preclinical Testing Consortium; T-ALL, T-cell acute lymphoblastic leukemia. 39

OBI-3424 正在進行中之臨床試驗係以肝細胞癌 (Hepatocellular Carcinoma, HCC) 以及對去勢療法產生抗藥性之攝護腺癌 (Castrate-Resistant Prostate Cancer, CRPC) 患者為受試對象 局部晚期或已轉移之 HCC, CPRC Part 1 劑量遞增階段 OBI-3424 Part 2 族群擴增階段 OBI-3424 以 IDE-Approved Assay 量測 AKR1C3 酵素的表現量 Apostolia M Tsimberidou, MD, PhD Department of Investigational Cancer Therapeutics Division of Cancer Medicine Clinicaltrials.gov. This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. NCT03592264 40

%hucd45+ in the PB OBI-3424 在 PDX 動物模型 (T-ALL 31) 明顯降低白血病之骨髓浸潤 Control Group Significant Difference in Event-Free Survival (EFS) OBI-3424 Group OBI-3424 is one of the most effective drugs we have ever tested against T-ALL in over 12 years of evaluating drugs at the Children s Cancer Institute using preclinical models of childhood ALL Prof Richard B. Lock Head of the Leukemia Biology Program Children s Cancer Institute in Australia Days post-treatment initiation PB, peripheral blood; PDX, patient-derived xenograft. OBI Press Release 30 Oct 2017: OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 41

Globo Series 腫瘤醣抗原具備與其他抗癌標靶結合開發出創新雙特異抗體 (Bispecific Antibody) 的潛力 其他抗癌靶點 GLOBO SERIES 腫瘤醣抗原 PD-L1 Globo H SSEA4 + OX-40 CD-137 CD-40 創新之雙特異性抗體 VEGF VEGF, vascular endothelial growth factor. 42

Agenda 1 2 3 4 Company Introduction Globo Series Science Leadership Novel Cancer Pipeline Key Milestones and Inflection Points 43

浩鼎研發中產品全球智財權保護 49 63 109 158 2017 2018 Approved Patents 2017 2018 Patents in Review Includes Patents Held By Licensors. 44

於 2018 年達成之主要研發里程碑 獲美國 FDA 准予進行臨床試驗 獲美國 FDA 准予進行臨床試驗 獲美國 FDA 授予治療胰臟癌 (Pancreatic Cancer) 之孤兒藥資格 獲美國 FDA 授予治療急性淋巴性白血病 (Acute Lymphoblastic Leukemia, ALL) 之孤兒藥資格獲美國 FDA 授予治療肝細胞癌 (Hepatocellular Carcinoma, HCC) 之孤兒藥資格 啟動以三陰性乳癌 (TNBC) 患者為受試對象之全球三期臨床試驗 Clinicaltrials.gov. This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. NCT03573544 Clinicaltrials.gov. This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. NCT03592264 Clinicaltrials.gov. Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. NCT03562637 45

主要研發里程碑與價值轉折點 (2019-2023) Adagloxad Simolenin 啟動以三陰性乳癌 (TNBC) 為適應症之全球三期臨床試驗 收案完成 期中分析 解盲 (IDFS) OBI-888 Globo H mab Part 1 劑量遞增階段 Part 1 Data Part 2 族群擴增階段 Part 2 Data 2018 2019 2020 2021 2022 2023 OBI-999 Globo H ADC Submit IND P1 P1 Data P2 P2 Data OBI-3424 小分子化療前驅藥 Phase IND 1 Submitted Part 1 劑量遞增階段 Escalation Part 1 Data Part 2 族群擴增階段 Expansion Part 2 Data 46 IDFS, invasive disease-free survival.

浩鼎創新多元的抗癌產品線 1 2 3 4 全球 Globo Series 醣新藥研發的領導者, 研發領域包括以 Globo H 以及 SSEA-4 為作用標的之治療性疫苗 單株抗體, 以及抗體小分子藥物複合體 Globo Series 具備與其他抗癌標靶結合, 開發具綜效之雙特異性抗體 (Bispecific Antibodies) 潛力 被腫瘤內 AKR1C3 酵素活化之首創小分子化療前驅藥 (prodrug) 量測腫瘤抗原表現之檢驗試劑 全球智財權保護 數個研發里程碑與價值轉折點 (2019-2020) 47

THANK YOU Please visit our website: www.obipharma.com